BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave Therapeutics’ assets
BioNTech has reached a research and option agreement with Biotheus for two antibody candidates.
Biotheus announced the deal Wednesday. It will grant BioNTech exclusive worldwide options for a preclinical bispecific and a clinical-stage monoclonal antibody for undisclosed cancer targets in exchange for an upfront payment. If BioNTech chooses to license the preclinical candidate, Biotheus will get milestone payments and royalties. The financial specifics were not disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.